Collaborations
Collaborations
In the area of external collaboration, we aim to establish long-term partnership relationships, striving to be the preferred partner for global enterprises and institutions. We actively seek partners for global development and commercialization of products.
We are actively looking for the following types of collaboration opportunities
Cure Genetics, based on its unique technology platform, has incubated several pioneering cell therapy pipelines. The first pipeline targeting clear cell renal cell carcinoma has shown safety and efficacy in clinical research and can be concurrently expanded to other autologous/allogeneic/in vivo pipelines. We are seeking global partners for external product licensing or collaborative development.
Our AAV vector development platform VELP, with its effective library diversity and low mis-packing rate, combined with DNA nuclear enrichment-RNA signal detection technology, has already completed multiple licensing collaborations. We are actively promoting the translation of gene therapy products targeting the nervous system, heart, and kidneys based on the platform. We are also actively seeking global partners for joint exploration based on gene therapy platforms.
We are open to introducing innovative clinical stage projects that have the potential to address unmet clinical needs, to expand our layout in cell and gene therapy pipelines for solid tumors and genetic diseases.
We maintain a continuous development attitude towards early scientific research and actively collaborate with research institutions, start-ups, and other organizations for early R&D.
For more information, please contact
BD@curegenectis.com
